Symfi, Symfi Lo, and Cimduo for HIV
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
The Medical letter on drugs and therapeutics - 61(2019), 1563 vom: 14. Jan., Seite e8-e10 |
| Sprache: |
Englisch |
|---|
| Anmerkungen: |
Date Completed 13.02.2019 Date Revised 09.12.2020 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM293090246 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293090246 | ||
| 003 | DE-627 | ||
| 005 | 20231225074542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0976.xml |
| 035 | |a (DE-627)NLM293090246 | ||
| 035 | |a (NLM)30681663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Symfi, Symfi Lo, and Cimduo for HIV |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.02.2019 | ||
| 500 | |a Date Revised 09.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atripla | |
| 650 | 4 | |a Cimduo | |
| 650 | 4 | |a Complera | |
| 650 | 4 | |a Epzicom | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a NNRTIs | |
| 650 | 4 | |a Odefsey | |
| 650 | 4 | |a Symfi | |
| 650 | 4 | |a abacavir | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a cobicistat | |
| 650 | 4 | |a dosage | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a efavirenz | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a emtricitabine | |
| 650 | 4 | |a emtricitabine/tenofovir | |
| 650 | 4 | |a lamivudine | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a rilpivirine | |
| 650 | 4 | |a ritonavir | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a tenofovir | |
| 650 | 4 | |a tenofovir alafenamide | |
| 650 | 7 | |a 9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenine |2 NLM | |
| 650 | 7 | |a Alkynes |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Benzoxazines |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Phosphorous Acids |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 650 | 7 | |a efavirenz, lamivudine, tenofovir disoproxil fumarate drug combination |2 NLM | |
| 650 | 7 | |a lamivudine, tenofovir disoproxil fumarate drug combination |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 650 | 7 | |a efavirenz |2 NLM | |
| 650 | 7 | |a JE6H2O27P8 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical letter on drugs and therapeutics |d 1965 |g 61(2019), 1563 vom: 14. Jan., Seite e8-e10 |w (DE-627)NLM000074810 |x 1523-2859 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2019 |g number:1563 |g day:14 |g month:01 |g pages:e8-e10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2019 |e 1563 |b 14 |c 01 |h e8-e10 | ||